DNA Microarrays in Drug Discovery and Development

[1]  M. Nishiyama.  [Polygenetic pharmacogenomic strategies to identify drug sensitivity biomarkers]. , 2005, Gan to kagaku ryoho. Cancer & chemotherapy.

[2]  T. Singer,et al.  Toxicogenomics in the pharmaceutical industry: hollow promises or real benefit? , 2005, Mutation research.

[3]  R. Stoughton.  Applications of DNA microarrays in biology. , 2005, Annual review of biochemistry.

[4]  Peng Li,et al.  Gene expression analysis of peroxisome proliferators- and phenytoin-induced hepatotoxicity using cDNA microarray. , 2004, The Journal of veterinary medical science.

[5]  Ian Pate,et al.  Phenotypic Anchoring of Gene Expression Changes during Estrogen-Induced Uterine Growth , 2004, Environmental health perspectives.

[6]  A. Parissenti,et al.  The use of DNA microarrays to investigate the pharmacogenomics of drug response in living systems. , 2004, Current topics in medicinal chemistry.

[7]  Kerry Blanchard,et al.  Integration of clinical and gene expression endpoints to explore furan-mediated hepatotoxicity. , 2004, Mutation research.

[8]  N. Biguet,et al.  DNA microarrays and pharmacogenomics. , 2004, Pharmacological research.

[9]  R. Tennant,et al.  Identification of putative gene based markers of renal toxicity. , 2004, Environmental health perspectives.

[10]  L. Babiss,et al.  Toxicogenomics in predictive toxicology in drug development. , 2004, Chemistry & biology.

[11]  T. Dingermann,et al.  A new approach to studying ochratoxin A (OTA)-induced nephrotoxicity: expression profiling in vivo and in vitro employing cDNA microarrays. , 2003, Toxicological sciences : an official journal of the Society of Toxicology.

[12]  Hiroyoshi Taniguchi,et al.  Relevance network between chemosensitivity and transcriptome in human hepatoma cells. , 2003, Molecular cancer therapeutics.

[13]  W. Pennie.  Custom cDNA microarrays; technologies and applications. , 2002, Toxicology.

[14]  A. Kong,et al.  Application of DNA Microarrays in Pharmacogenomics and Toxicogenomics , 2002, Pharmaceutical Research.

[15]  John Quackenbush.  Microarray data normalization and transformation , 2002, Nature Genetics.

[16]  S. Wiseman,et al.  Applications of DNA and protein microarrays in comparative physiology. , 2002, Biotechnology advances.

[17]  Andrew J. Holloway,et al.  Options available—from start to finish—for obtaining data from DNA microarrays II , 2002, Nature Genetics.

[18]  D. Gerhold,et al.  Better therapeutics through microarrays , 2002, Nature Genetics.

[19]  C. Ball,et al.  Microarray databases: standards and ontologies , 2002, Nature Genetics.

[20]  S. Ramaswamy,et al.  Translation of microarray data into clinically relevant cancer diagnostic tests using gene expression ratios in lung cancer and mesothelioma. , 2002, Cancer research.

[21]  T. Speed,et al.  Design issues for cDNA microarray experiments , 2002, Nature Reviews Genetics.

[22]  S. Gruvberger,et al.  BioArray Software Environment (BASE): a platform for comprehensive management and analysis of microarray data , 2002, Genome Biology.

[23]  K. Becker,et al.  Dissecting the Circuitry of Protein Kinase A and cAMP Signaling in Cancer Genesis , 2002, Annals of the New York Academy of Sciences.

[24]  Angela Relógio,et al.  Optimization of oligonucleotide-based DNA microarrays. , 2002, Nucleic acids research.

[25]  M. King,et al.  BRCA1 transcriptionally regulates genes involved in breast tumorigenesis , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[26]  Jorge R. Oksenberg,et al.  Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis , 2002, Nature Medicine.

[27]  J. Blumenstock,et al.  Global Analysis of Gene Expression: Methods, Interpretation, and Pitfalls , 2002, Nephron Experimental Nephrology.

[28]  L. K. Buehler,et al.  Normalizing DNA microarray data. , 2002, Current issues in molecular biology.

[29]  Jean-Marie Rouillard,et al.  OligoArray: genome-scale oligonucleotide design for microarrays , 2002, Bioinform..

[30]  C. Handschin,et al.  A Link between cholesterol levels and phenobarbital induction of cytochromes P450. , 2002, Biochemical and biophysical research communications.

[31]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[32]  T. Poggio,et al.  Prediction of central nervous system embryonal tumour outcome based on gene expression , 2002, Nature.

[33]  E. Rosen,et al.  Altered gene expression pattern in cultured human breast cancer cells treated with hepatocyte growth factor/scatter factor in the setting of DNA damage. , 2001, Cancer research.

[34]  D. Soprano,et al.  Cross-resistance to the synthetic retinoid CD437 in a paclitaxel-resistant human ovarian carcinoma cell line is independent of the overexpression of retinoic acid receptor-gamma. , 2001, Cancer research.

[35]  R E Stoll,et al.  Assessment of cisplatin-induced nephrotoxicity by microarray technology. , 2001, Toxicological sciences : an official journal of the Society of Toxicology.

[36]  Pat Levitt,et al.  Analysis of complex brain disorders with gene expression microarrays: schizophrenia as a disease of the synapse , 2001, Trends in Neurosciences.

[37]  K. Becker,et al.  Antisense DNAs as multisite genomic modulators identified by DNA microarray , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[38]  M. Ringnér,et al.  Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks , 2001, Nature Medicine.

[39]  N. Kaminski,et al.  The use of microarrays in medicine. , 2001, The Israel Medical Association journal : IMAJ.

[40]  Hisham K. Hamadeh,et al.  Gene Chips and Functional Genomics , 2000, American Scientist.

[41]  N. Lee,et al.  A concise guide to cDNA microarray analysis. , 2000, BioTechniques.

[42]  A. Brazma,et al.  Gene expression data analysis , 2000, FEBS letters.

[43]  M. Bittner,et al.  Monitoring the expression profiles of doxorubicin-induced and doxorubicin-resistant cancer cells by cDNA microarray. , 2000, Cancer research.

[44]  Yudong D. He,et al.  Functional Discovery via a Compendium of Expression Profiles , 2000, Cell.

[45]  Lennon,et al.  High-throughput gene expression analysis for drug discovery. , 2000, Drug discovery today.

[46]  J. Mesirov,et al.  Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. , 1999, Science.

[47]  J. Barrett,et al.  Application of complementary DNA microarray technology to carcinogen identification, toxicology, and drug safety evaluation. , 1999, Cancer research.

[48]  W. Gerald,et al.  The Wilms Tumor Suppressor WT1 Encodes a Transcriptional Activator of amphiregulin , 1999, Cell.

[49]  Andrius Kazlauskas,et al.  Diverse Signaling Pathways Activated by Growth Factor Receptors Induce Broadly Overlapping, Rather Than Independent, Sets of Genes , 1999, Cell.

[50]  M. Schena,et al.  Overview of DNA chip technology , 1999, Molecular breeding.

[51]  J. Trent,et al.  Microarrays and toxicology: The advent of toxicogenomics , 1999, Molecular carcinogenesis.

[52]  D. Botstein,et al.  Cluster analysis and display of genome-wide expression patterns. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[53]  Michael Ruogu Zhang,et al.  Comprehensive identification of cell cycle-regulated genes of the yeast Saccharomyces cerevisiae by microarray hybridization. , 1998, Molecular biology of the cell.

[54]  P. Brown,et al.  Drug target validation and identification of secondary drug target effects using DNA microarrays , 1998, Nature Medicine.

[55]  R. W. Davis,et al.  Discovery and analysis of inflammatory disease-related genes using cDNA microarrays. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[56]  Ronald W. Davis,et al.  Quantitative Monitoring of Gene Expression Patterns with a Complementary DNA Microarray , 1995, Science.

[57]  B. O'dowd,et al.  A single amino-acid difference confers major pharmacological variation between human and rodent 5-HT1B receptors , 1992, Nature.

[58]  Michael E. Greenberg,et al.  Stimulation of 3T3 cells induces transcription of the c-fos proto-oncogene , 1984, Nature.

[59]  E. Southern.  Detection of specific sequences among DNA fragments separated by gel electrophoresis. , 1975, Journal of molecular biology.

[60]  S. Albertini,et al.  Effect of two 5-HT6 receptor antagonists on the rat liver: a molecular approach , 2003, The Pharmacogenomics Journal.

[61]  M. Heller.  DNA microarray technology: devices, systems, and applications. , 2002, Annual review of biomedical engineering.

[62]  P. Bugelski.  Gene expression profiling for pharmaceutical toxicology screening. , 2002, Current opinion in drug discovery & development.

[63]  G. Hannon,et al.  RNA interference , 2002, Nature.

[64]  A. Coulson,et al.  RNA-Mediated Interference as a Tool for Identifying Drug Targets , 2001, American journal of pharmacogenomics : genomics-related research in drug development and clinical practice.

[65]  D. Bowtell,et al.  Options available — from start to finish — for obtaining expression data by microarray , 1999, Nature Genetics.

[66]  D. Botstein,et al.  The transcriptional program in the response of human fibroblasts to serum. , 1999, Science.

[67]  P. Goodfellow,et al.  DNA microarrays in drug discovery and development , 1999, Nature Genetics.

[68]  Manley Jl,et al.  Transcription of mammalian genes in vitro. , 1981 .

[69]  W. Marzluff.  Chapter 27. Transcription of RNA in Isolated Nuclei , 1978 .